surpass cvot tirzepatide results ๐ซ EASD 2025: (SURPASS-CVOT) Dulaglutide head-to-head showdown: โ Noninferior for MACE โ 16% โ all-cause mortality โ Superior in A1C & weight loss Tirzepatide confirms its broad cardiometabolic edge. #EASD2025 # Tirzepatide #GLP1 Effect of tirzepatide versus insulin
Pay in 4 interest-free payments of $5.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Sep 8 - Sep 13





01774-X/asset/3608bfb3-6329-4132-95b7-cc3434437493/main.assets/gr2_lrg.jpg)



















